Rhythm Pharmaceuticals at Stifel 2026 Healthcare Conference: launch gains pace

On November 11, 2026, Rhythm Pharmaceuticals announced at the Stifel Healthcare Conference 2026 that its IMCIVREE launch for acquired hypothalamic obesity is gaining traction, while its next-generation pipeline is advancing toward later-stage development. The company highlighted strong early prescription growth but cautioned about near-term cash burn, regulatory challenges abroad, and increased spending expected in 2027.

Since March 2024, when the FDA approved IMCIVREE, the company has launched over 700 start forms for the treatment. Approximately 500 unique healthcare providers have written prescriptions, with 25% being repeat prescribers. Rhythm anticipates Japan and Europe as significant growth drivers, with Europe expected to have launches in 2027.

The company is advancing bivamelagon as its lead next-generation asset after renegotiating its royalty deal with LG Chem. CFO Hunter Smith mentioned that the company is self-sustaining but expects spending to surge in 2027 due to clinical work, international launches, and other factors.

Most prescriptions are coming from tier 1 and tier 2 endocrinologists, indicating a larger addressable market than initially identified. Smith noted that prescriptions are often written during routine visits for hormonal follow-ups rather than due to active patient calls. He also explained that many AHO patients have additional hormone deficiencies, leading to regular touchpoints with endocrinologists.

Rhythm is in a self-sustaining position and does not require external equity capital for near-term operations. The company secured a term loan to fund its royalty buyout with LG Chem and to maintain a liquidity cushion during cash burn. Management expects cash use to normalize as IMCIVREE revenue grows and operations become more efficient.

Spending is anticipated to rise substantially in 2027, driven by two Phase III bivamelagon studies, chemistry, manufacturing, and controls work, and the expansion of IMCIVREE into Europe and Japan. Japan is a crucial new market after IMCIVREE received approval there in October 2024 for AHO. The company estimates around 5,000 to 8,000 potential patients in Japan, compared to about 10,000 in the United States, due to a higher incidence of craniopharyngioma, a primary cause of AHO.

The first 12 months post-launch are limited by a rule requiring bi-weekly prescription renewals, leading to modest growth. Stronger growth is expected after these restrictions ease. Rhythm is also focusing on market access in the EU4 countries and the United Kingdom, with launches planned throughout 2027.